Accelerated bone growth, but impaired implant fixation in allograft bone mixed with nano-hydroxyapatite - an experimental study in 12 canines

Lau Lind Petersen1*, Jørgen Baas1, Mette Sørensen1, Joan E. Bechtold2, Kjeld Søballe1 and Jeppe Barckman1

Introduction
Overcoming bone loss is a common challenge during revision of failed prostheses, and impaction-grafting is a well-established method to counter this problem [14, 28]. The gold standard of bone graft is autograft bone [12], but it has several disadvantages including donor site morbidity and limited amounts for grafting larger defects [34]. Although allograft bone is inferior to autograft bone in terms of osteoinduction and osteogenicity [13], allograft is most often chosen due to its higher availability, known osteoconductivity and absence of donor site morbidity [24, 32].

The demand for primary hip prostheses rising markedly as the population ages [11]. With a 10% risk of revision within the first decade of primary hip replacement [17], the absolute number of people who require revision of failed hip prostheses also thereby is expected to increase. Furthermore, revision prostheses have higher failure rates, with up to 26% risk of failure within the first 10 years [27]. Failures are mostly due to aseptic loosening, which is thought to be related to reduced osseointegration and early implant subsidence due to bone loss that prevents adequate initial fixation [10, 29].

Nano-hydroxyapatite (nHA) is widely used in dentistry and orthopedics as a bone substitute or bone graft extender [20, 30]. Several studies have shown nHA to have osteoconductive and some osteoinductive properties [2, 8, 9, 15, 18–21, 25, 26]. Tibia plateau defects have been filled with nHA with promising results regarding bone healing [20]. An in vitro experiment has demonstrated that the physical presence of nHA does not impede the mechanical stability of the impacted graft material at concentrations of 10% nHA. At 33% nHA, however, the mechanical stability seems to decline [2].

To our knowledge, the combination of morselized allograft bone and nHA have never been studied regarding osseointegration of grafted implants in vivo. Osti® which is a paste of 35% volume nHA particles and 65% water was used for this study.

The aim of the study is to evaluate the effect of nHA augmented graft on implant fixation. It was hypothesized, that the nHA would serve as a conductor for new bone ingrowth within the grafted defect, thereby increasing bone growth and thus improving implant fixation.

Methods and materials
Design, location and ethical approval
This experiment was conducted as a double-paired animal study. A well-established peri-implant gap model [31] was employed in which impacted allograft bone with or without addition of nHA was compared. A total of 12 skeletally mature Class A American Hounds were included with a mean age of 11 (10–15) months and a mean weight of 32 (29–36) kg. The hounds were bred for scientific purposes and had individual cages. They were fed ad-libitum standard dog food (21% Lab Dog Diet #8755, Teklad Diets, Madison WI). Two additional
animals were used as allograft bone donors. For this study, each animal received four implants, two in each distal femur (Fig. 1). Surgery and post-operative care were carried out at a facility in Minneapolis, licensed with USDA and AAALAC. This study was approved by the International Animal Care and Use Committee.

A total of 48 titanium alloy implants (Ti-6Al-4V) were used with a porous coating used on commercially available hip prostheses (manufactured and donated by DePuy Inc. (Warsaw, IN, USA)). The implants consist of a solid cylindrical core with a height of 10 mm and a diameter of 6 mm. An 11-mm end-screw was attached in both ends (Fig. 2). This created a 2.5 mm concentric peri-implant gap around the core of the implant when inserted into an 11-mm drill hole. The gap around the control implants were impacted with morselized allograft bone. In the intervention groups the bone graft impacted into the gap was augmented with either a low dose (5% of volume) nHA (nHA Low) or high dose (20% of volume) nHA (nHA High). There were two paired groups. In the lateral condyle: nHA Low vs. Control 1 and in the medial condyle: nHA High vs. Control 2 (Fig. 1). This way, only contralateral condyles were compared in order to rule out any potential difference between the lateral and the medial condyle. The groups were also randomly distributed between left and right.

Allograft bone

Bone graft was harvested under sterile conditions from two donor animals not included in this study. The proximal humeri, the proximal tibiae and the distal femora were used. The donor animals were not genetically connected to the recipients, thus ensuring non-histocompatibility as in the clinical situation with human allograft. Prior to preparation, all soft tissue and cartilage was removed, and the bones were morselized using a standard bone mill (Biomet® , Warsaw, IN, USA) creating bone chips of 1–3 mm in size.

The volume of bone in the 2.5 mm circumferential gap of this model is 0.67 cm³. Results from prior studies show that approximately 1.38 g of morselized bone can be impacted into this gap [4]. Sixteen portions of bone graft were prepared for each of the four experimental groups. A total of 89 g bone graft (64 portions of 1.38 g)
was rinsed by gentle stirring in 890 ml saline at a temperature of 37 °C for 1 min and repeated three times with fresh saline. The rinsed bone graft was divided into four groups, each group sub-divided into 16 equal portions (4 of which were extras in case needed) and stored in sterile double-containers at −80 °C. The bone graft was rinsed to remove excess fat and loose connective tissue, enabling an addition of a larger volume of nHA-paste to the bone graft.

**Preparation of the nHA bone graft mixture**

Ostim® was used (Heraeus Kulzer Nordic AB, Kolding, Denmark) as a pH neutral source of nHA. Ostim® is a mouldable paste and provides no structural stability itself [18]. Having the same inorganic components as human bone, nHA has been shown to have high osteoconductivity. The size of the nHA particles (100x20x3 nm) are shown to accelerate neovascularization [25].

To facilitate mixing of the nHA in bone graft, the Ostim® paste was diluted by adding sterile saline in a 1:1 ratio. To ensure an even dispersion of the nHA into the allograft bone, the substances were mixed twice. Firstly, the allograft bone from each group was divided into 16 samples, to which nHA was added. Secondly, all 16 samples from each group were pooled, and mixed thoroughly. Finally, the groups were divided into 16 portions again, stored in double sterile containers, and frozen at −80 °C.

**Surgery**

Under general anaesthesia and sterile conditions, the femoral epicondyles were exposed through medial and lateral incisions. The periosteum was divided and loosened from the bone with a rongeur. A 2.5-mm guide wire was inserted perpendicular to the surface of the epicondyle 18 mm from the distal edge of the condyle and 14 mm from the anterior edge of the condyle. A drill speed of maximum two rotations per second was used to avoid thermal tissue damage. The drill hole was 11 mm wide and 12 mm deep. The implant with its 2.5 mm end-screw attached was inserted into the drill hole. With a specially designed hollow impaction tool, the peri-implant gap was impacted with bone graft. To ensure homogeneous distribution of the graft in the defect, one third of the graft was impacted into the bottom third of the gap, then one third of the graft was impacted into the middle third of the gap, and finally, the remaining graft was impacted into the most superficial third of the gap. Impaction was done by hand force and by the same surgeon. Finally, the top screw was screwed into the threaded implant core, and the incision closed in layers. Following closure, Bupivacaine 0.5% was administered locally at the incision site. Postoperatively, each animal received a transdermal Fentanyl patch (75 μg/h) for three days. The animals rested in separate cages and were allowed unrestricted weight bearing and daily exercise. Observation time was four weeks. Euthanasia was performed with acepromazine (0.5 mg/kg), an anaesthetic dose of propofol (4 mg/kg), followed by an injection of hypersaturated barbiturate. Afterwards, the distal femora were harvested, cleaned and frozen at −80 °C. One surgeon performed all surgeries.

**Specimen preparation**

Implant-bone specimen blocks were cut out of the bone on a water-cooled diamond band saw (Exact Apparatebau, Nordenstedt, Germany). The top-screw and the most superficial 1 mm of the implant were removed and discarded. The remaining 9 mm of the implant was divided into two sections. The outermost 3 mm was stored at −20 °C pending the mechanical push-out test. The remaining 6 mm (Fig. 3) was dehydrated in graded alcohol (70%, 96% and 100%), 2-propanol, and xylene and embedded in methylmethacrylate (Art. 800,590, Merck, Darmstadt, Germany), and prepared for the histomorphometric analysis.

For the histomorphometry, each specimen was rotated around its vertical axis prior to sectioning. This produced randomly defined sectioning planes. Using vertical sectioning technique [3] four 30-μm sections were cut on a glycerol-cooled microtome (KDG-95-MeProTech, Heerhugowaard, The Netherlands). Each section was surface stained with 0.1% toluidine blue (pH = 7, Fluka, Sigma-Aldrich, St. Louis, MO, USA) for 10 min, rinsed and mounted on glass.

![Fig. 3 Sections of the implants for mechanical and histomorphometric testing](image-url)
Mechanical testing
We conducted the mechanical testing on an MTS Bionics Test Machine (MTS 858 Mini Bionix, MN, USA, Software: MTS Test Star 790.00 Version 4.0C). The test was performed blinded and in one session. Each specimen was placed over a 7.4-mm hole and a 5-mm cylindrical test probe was used. With a preload of 2 N and at a rate of 5 mm/min, the implant was pushed out of the surrounding tissue (Fig. 4). Load versus displacement data was continuously recorded and the mechanical parameters (maximum shear strength, apparent shear stiffness, and total energy absorption) were derived [31].

Histomorphometric analysis
On each histological section, blinded histomorphometric analysis was performed using 10x magnification. The stereological software was used C.A.S.T Grid (newCAST-version 3.4.1.0; Visiopharm A/S, Horsholm, Denmark). Two regions of interest were defined: The Inner Gap ranging from the mid part of the porous coating of the implant to 500 μm into the gap and the Outer Gap, ranging from 500 to 2000 μm further into the gap (Fig. 5). Volume fractions were quantified by point-counting technique [16] and surface ongrowth was quantified by line intercept technique [3]. New bone, fibrous tissue, graft bone, and bone marrow space were assessed (Fig. 6). Osteoid was included as new bone.

Statistics
Stata 11.2 (StataCorp, College Station, TX, USA) was used for statistical analyses. Mechanical data were normally distributed as evaluated by q-norm plots of the residuals. The histomorphometric data were normally distributed, except for volume and surface ongrowth of fibrous tissue. All parametric data was analyzed with a two-tailed Student’s t-test. Results are presented as mean with standard deviation (SD). For non-parametric data, we used the Wilcoxon Signed Rank test and the results are presented as median with interquartile range (IQR). Statistical significance was considered for p-values less than 0.05.

Results
All animals recovered fully, but two weeks postoperatively one animal needed debridement of the knee joint due to superficial infection. The consulting veterinarian performed an open lavage of the knee joint but left the implants untouched and it healed uneventfully. Another animal needed re-suture of the superficial layers. Otherwise, all animals healed uneventfully.

For all mechanical parameters, the Control implants were comparable to the Low dose nHA implants. The High-dose nHA implants had statistically significantly inferior stiffness compared to the Control implants (mean 15.2 vs 24.5) \( p = 0.01 \); Fig. 7). Histomorphometrically, a relative 45% increase in new bone volume and a relative 44% increase in new bone surface coverage was found when comparing the nHA High group to control (Table 1). No statistically significant differences were found when the nHA low group was compared with its control regarding osseointegration (Table 2).

Discussion
In this study, we found that augmenting morselized allograft bone with nHA paste increased new bone formation, but weakened the fixation of titanium implants at a high dose of nHA.
The implant model is a well-established model of a large peri-implant gap. It has been used for many years and enabled the evaluation of both the mechanical fixation and osseointegration of the same implant. The simplicity of this implant model secures a high degree of variance control. However, it has some limitations. The grafted implants were not influenced by direct load or joint fluid. Additionally, surgery was performed on
young healthy animals with a bone quality not compromised by the presence of a failed primary implant. Dogs were chosen due to their close resemblance in bone biology to human bone [1].

The hypothesis of this study was adding nHA to the bone graft would increase its osteoconductivity and osteoinductivity leading to improved new bone formation and thereby improved implant fixation. Ostim® was chosen as the source of nHA due to its mouldable consistency and high biocompatibility [18], but other formulations may not behave the same. The small nHA particles may have been able to partially fill the empty space between the allograft bone pieces without increasing the total volume of the impacted bone graft, hence the graft amount was not changed among groups. Laterality was assumed to possibly influence healing, so only medial right and left implants were compared with each other, as well as lateral right and left implants were compared. The observation period of 4 weeks was chosen based on previous experience with graft resorption and new bone formation in the same animal model [6].

Augmenting bone graft with nHA led to increased bone formation. This biologic response was observed both in the grafted region surrounding the implant as well as directly on the implant surface.

### Table 1: Histomorphometric results of Control 1 vs nHA Low, SD standard deviation, IQR interquartile range

| Implant surface | New bone mean % (SD) | Fibrous tissue median % (IQR) | Bone graft mean % (SD) |
|-----------------|----------------------|-------------------------------|------------------------|
| Control 1       | 22 (9.9)             | 2 (0–9)                       | 1 (0.42)               |
| nHA Low         | 27 (12.7)            | 4 (0–14)                      | 1 (0.38)               |
| t-test          | p = 0.17             |                               | p = 0.27               |
| Wilcoxon        |                      |                               | p = 0.53               |
| Inner gap (0–500 μm) |                 |                               |                        |
| Control 1       | 29 (12)              | 2 (0–6)                       | 7 (2.9)                |
| nHA Low         | 34 (0.13)            | 1 (0–9)                       | 6 (3.5)                |
| t-test          | p = 0.25             |                               | p = 0.42               |
| Wilcoxon        |                      |                               | p = 0.45               |
| Outer gap (500–2000 μm) |              |                               |                        |
| Control 1       | 25 (6.4)             | 0 (0–1)                       | 14 (3.9)               |
| nHA Low         | 30 (6.2)             | 0 (0–1)                       | 14 (4.4)               |
| t-test          | p = 0.06             |                               | p = 0.89               |
| Wilcoxon        |                      |                               | p = 0.91               |

### Table 2: Histomorphometric results of Control 2 vs nHA High, SD standard deviation, IQR interquartile range

| Implant surface | New bone mean % (SD) | Fibrous tissue median % (IQR) | Bone graft mean % (SD) |
|-----------------|----------------------|-------------------------------|------------------------|
| Control 2       | 18 (6.5)             | 1 (0–8)                       | 1 (1.1)                |
| nHA High        | 26 (7.9)             | 3 (0–5)                       | 1 (0.6)                |
| t-test          | p = 0.011            |                               | p = 0.56               |
| Wilcoxon        |                      |                               | p = 0.97               |
| Inner gap (0–500 μm) |                 |                               |                        |
| Control 2       | 25 (7.3)             | 1 (0–5)                       | 7 (3.6)                |
| nHA High        | 31 (7.1)             | 0 (0–6)                       | 8 (4.1)                |
| t-test          | p = 0.048            |                               | p = 0.48               |
| Wilcoxon        |                      |                               | p = 0.72               |
| Outer gap (500–2000 μm) |              |                               |                        |
| Control 2       | 20 (5.2)             | 0 (0–1)                       | 14 (4.7)               |
| nHA High        | 29 (6.2)             | 0 (0–1)                       | 16 (4.6)               |
| t-test          | p = 0.001            |                               | p = 0.197              |
| Wilcoxon        |                      |                               | p = 0.48               |
of new bone was statistically significantly higher for the High-dose nHA group, but not for the Low-dose group.

The purpose of stimulating new bone formation is to achieve a solid mechanical anchorage of the implant in living bone to sustain implant stability, durability and survival. However, no improvement of the mechanical fixation of the implants was found in the nHA-augmented implants. In the High-dose nHA group, a statistically significant decrease in mechanical implant fixation was observed.

The phenomenon of increased bone formation and weakened mechanical implant fixation has been observed in many previous experiments seeking to stimulate new bone formation [6]. Many of these experiments have shown that increased new bone formation is coupled to an increased resorption of bone graft [7] as well as resorption of newly formed bone leading to a transient weakening of the implant anchorage pending remodelling to lamellar bone [22].

In the current experiment with nHA no changes in the amounts of bone graft between the groups were found, rendering the above explained phenomenon unlikely in this case. A longer observation period may have resulted in a more complete remodelling towards lamellar bone yielding a more rigid fixation. The observation period of 4 weeks was chosen to evaluate the effect on early implant fixation as this correlates to later implant loosening [23].

Arts et al. [2] mixed nHA with bone grafts in a study with two separate models, one testing mechanical strength in vitro, another measuring histological bone growth in vivo on rabbits. At 10% nHA, mechanical strength increased, and at 33% increased bone growth was observed in the rabbit model. Mechanical strength, however, decreased at 33% nHA. Their study design did not allow both mechanical and histomorphometric analysis on the same specimen. Also, no titanium implants were used. With the current study design, it was possible to analyze bone growth and mechanic stability around a porous-coated titanium implant. A 5% addition of nHA was chosen for the nHA Low group and 20% for the High group. Accordingly, a four-fold difference between the high dose and the low dose intervention was seen with the high dose below their 33% nHA. These results show an increased bone growth, but at the cost of mechanical strength with 20% nHA (again with the caveat that there was only one observation period, at 4 weeks). This concurs with Arts and coworkers’ while maintaining site-specific control [2].

A reason for the impaired mechanical fixation observed in the high dose group may have been related to the 20% dose of nHA. The study was designed as a doubled paired study in order to reduce biological differences between medial and lateral femur epicondyly. For that reason, a middle group of 10% volume concentration could not be included, while maintaining site-specific control. It is unknown if 10% volume concentration would have favoured osseointegration without hampering the mechanical stability.

Although several studies have reported promising effects on bone healing with the use of nHA particles [19, 21], some have found remnant particles of nHA embedded in bone or fibrous tissue, even after longer periods of observation (up to 8 months) [15, 5]. Others have shown cell toxicity caused by nHA particles in lung and kidney tissue [33]. Another concern with the use of nHA augmented bone graft is the possibility that the nHA particles may cause wear on arthroplasty prostheses. These factors were not evaluated in the current model, but the concerns should be considered for eventual clinical use.

**Conclusion**

Within the limits of this model, this study found that adding nHA to allograft bone around a cylindrical implant results in increased new bone formation around the implant but with decreased mechanical anchorage of the implant in the surrounding bone. Early mechanical implant fixation is important to achieve good long-term implant survival. For this reason, it is premature to recommend this method in implant grafting procedures of joint replacements until further studies have been conducted evaluating different concentrations. It may, however, be of interest in other gap-filling grafting procedures in which early mechanical stability is not a surgical goal, since longer observation periods may improve the mechanical properties of the woven bone.

**Abbreviation**

nHA: Nano-hydroxyapatite.

**Authors’ contributions**
The author(s) read and approved the final manuscript.

**Declarations**

**Competing interests**
The porous coating on the titanium implants was donated unconditionally by DePuy Inc. (Warsaw, IN, USA). Ostim® was donated unconditionally by Heraeus Inc., and a reserve amount was purchased at retail price. Nis-Hansen’s Memorial Scholarship and Lundbeck Foundation supported this project.

**Author details**

1. Department of Orthopedics, Aarhus University Hospital Skejby, Palle Juul-Jensens Boulevard, 99 8200 Aarhus N, Denmark. 2. Departments of Orthopaedic Surgery and Biomedical Engineering, University of Minnesota Life Sciences, Building 700 South 10th Avenue, Minneapolis, MN 55415, USA.

Received: 29 November 2021   Accepted: 11 March 2022
Published online: 23 April 2022
References

1. Aerssens J, Boonen S, Lowet G, Dequeker J (1998) Interspecies differences in bone composition, density, and quality: potential implications for in vivo bone research. Endocrinology 139:663–670
2. Arts JJC, Verdonschot N, Schreurs BW, Buma P (2006) The use of a bioabsorbable nano-crystalline hydroxyapatite paste in acetabular bone impaction grafting. Biomaterials 27:1110–1118
3. Baddeley AJ, Gundersen HJ, Cruz-Orive LM (1986) Estimation of surface area from vertical sections. J Microsc 142:259–276
4. Barckman J, Baas J, Sorensen M, Bechtold JE, Soballe K (2013) Rinsing of allograft bone does not improve implant fixation: a study in 12 dogs. Acta Orthop 84:307–313
5. Bullens PHJ, Hannink G, Verdonschot N, Buma P (2010) No effect of dynamic loading on bone graft healing in femoral segmental defect reconstructions in the goat. Injury 41:1284–1291
6. Baas J (2008) Adjuvant therapies of bone graft around non-cemented experimental orthopedic implants stereological methods and experiments in dogs. Acta Orthop Suppl 79:1–43
7. Baas J, Lamborg A, Jensen TB, Ermengard B, Soballe K (2006) The bovine bone protein lyophilised Colllos improves fixation of allografted implants - an experimental study in dogs. Acta Orthop 77:791–798
8. Carmagnola D, Abati S, Celestino S, Chiapasco M, Bosshardt D, Lang NP (2008) Oral implants placed in bone defects treated with bio-Oss®(R), Ostim®(R)-paste or PerioGlas: an experimental study in the rabbit tibia. Clin Oral Implants Res 19:1246–1253
9. Chitsazi MT, Shirmohammadi A, Faramarzie M, Pourabbas R, Rostamzadeh A (2011) A clinical comparison of nano-crystalline hydroxyapatite (Ostim) and autogenous bone graft in the treatment of periodontal intrabony defects. Med Oral Patol Oral Cir Bucal 16:E488–E453
10. Elderidge JDJ, Smith EJ, Hubble MJ, Whitehouse SL, Learmonth ID (1997). Massive early subsidence following femoral impaction grafting. J Arthroplast 12:535–540
11. Fehring TK, Odum SM, Troyer JL, Iorio R, Kurtz SM, Lau EC (2010) Joint replacement access in 2016: a supply side crisis. J Arthroplast 25:1175–1181
12. Gambard SC, Lieberman JR (2003) Bone graft for revision hip arthroplasty: biology and future applications. Clin Orthop Relat Res 417:183
13. Giannoudis PV, Dinopoulos H, Tsiridis E (2005) Bone substitutes: an update. Injury 36(Suppl 3):S20–S27
14. Gie GA, Linder L, Ling RS, Simon JP, Slooff TJ, Timperley AJ (1993) Enhanced bone formation in the mini pig. Folia Histochem Cytobiol 48:589–596
15. Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K (1988) Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 96:379–394
16. Harris WH, Sledge CB (1990) Total hip and total knee replacement. N Engl J Med 323:725–731
17. Hassell WH, Sledge CB (1990) Total hip and total knee replacement. N Engl J Med 323:725–731
18. Huber FX, Belyaev O, Hillmeier J, Kock HJ, Huber C, Meeder PJ et al (2006) Calcium phosphate-based bone substitutes. Eur J Trauma 30:219–229
19. Karrholm J, Borsen B, Lowenheim G, Snorrason F (1994) Does early micromotion of femoral stem prostheses matter? 4-7-year stereoradiographic follow-up of 84 cemented prostheses. J Bone Joint Surg Br 76:912–917
20. Khan SN, Cammissa FP, Jr, Sandhu HS, Diwan AD, Girardi FP, Lane JM (2005) The biology of bone grafting. J Am Acad Orthop Surg 13:77–86
21. Laschke MW, Witt K, Pohlemann T, Menger MD (2007) Injectable nanocrystalline hydroxyapatite paste for bone substitution: in vivo analysis of biocompatibility and vascularization. J Biomed Mater Res Part B Appl Biomater 82B:494–505
22. Leuwandowski KU, Bondre SP, Wise DL, Tranotilo DJ (2003) Enhanced bioactivity of a poly (propylene fumarate) bone graft substitute by augmentation with nano-hydroxyapatite. Biomed Mater Eng 13:115–124
23. Lie SA, Havelin LI, Furnes ON, Engesaeter LB, Vollset SE (2004) Failure rates for 4762 revision total hip arthroplasties in the Norwegian arthroplasty register. J Bone Joint Surg Br 86:504–509
24. Lind M, Kiarup N, Mikkelsen S, Horycky E (2002) Exchange impaction allografting for femoral revision hip arthroplasty: results in 87 cases after 3.6 years’ follow-up. J Arthroplast 17:158–164
25. Malchau H, Herberts P, Ahnfeldt L (1993) Prognosis of total hip replacement in Sweden: follow-up of 92,675 operations performed 1978–1990. Acta Orthop 64:947–506
26. Schnettler R, Stahl JP, Alt V, Pavlidis T, Dingledein E, Wennisch S (2004) First histological observations on the incorporation of a novel nanocrystalline hydroxyapatite in the mini pig. Folia Histochem Cytobiol 48:589–596
27. Schipper J, Boonen S, Lowet G, Dequeker J (1998) Interspecies differences in bone composition, density, and quality: potential implications for in vivo bone research. Endocrinology 139:663–670
28. Schnettler R, Stahl JP, Alt V, Pavlidis T, Dingledein E, Wennisch S (2004) Calcium phosphate-based bone substitutes. Eur J Trauma 30:219–229
29. Schnettler R, Stahl JP, Alt V, Pavlidis T, Dingledein E, Wennisch S (2004) Calcium phosphate-based bone substitutes. Eur J Trauma 30:219–229
30. Schnettler R, Stahl JP, Alt V, Pavlidis T, Dingledein E, Wennisch S (2004) Calcium phosphate-based bone substitutes. Eur J Trauma 30:219–229
31. Schnettler R, Stahl JP, Alt V, Pavlidis T, Dingledein E, Wennisch S (2004) Calcium phosphate-based bone substitutes. Eur J Trauma 30:219–229
32. Schipper J, Boonen S, Lowet G, Dequeker J (1998) Interspecies differences in bone composition, density, and quality: potential implications for in vivo bone research. Endocrinology 139:663–670
33. Tingting D, Yang X, Hua L, Zhewei H, Jiao S (2012) Effect of particle size of hydroxyapatite nanoparticles on its biocompatibility. IEEE Trans NanobioScience. https://doi.org/10.1109/TNB.2012.2190418
34. Younger EM, Chapman MW (1989) Morbidity at bone graft donor sites. J Orthop Trauma 3:192–195

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.